Trial
NCT03803254
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
Kaiping Central Hospital; Guangzhou No.12 People's Hospital
Condition
Hepatocellular Carcinoma
Intervention
Hepatic arterial infusion chemotherapy
Why stopped
No participants enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-06